Snap Stock Upgraded to Buy: Analyst Sees 77% Upside
Snap upgraded to Buy with 77% upside; analysts expect first profit, rising subscriptions, and stronger growth ahead.
Already have an account? Sign in.
Snap upgraded to Buy with 77% upside; analysts expect first profit, rising subscriptions, and stronger growth ahead.
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
Critical Metals to buy European Lithium for $835M, gaining full control of a major rare earth project and boosting cash.